- Home
- MURA
MURA
Mural Oncology plc
as 12-18-2024 12:40pm EST
Stocks
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
| Founded: | 2013 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 57.2M | IPO Year: | N/A |
| Target Price: | $16.00 | AVG Volume (30 days): | 262.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.88 - $6.25 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mural Oncology plc (MURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Goodman Vicki L | MURA | Chief Medical Officer | Nov 7 '24 | Sell | $3.33 | 5,069 | $16,879.77 | 67,949 | |
| Cutler Adam D. | MURA | Chief Financial Officer | Oct 31 '24 | Sell | $3.41 | 7,421 | $25,305.61 | 71,438 |
Latest Mural Oncology plc News
MURA Breaking Stock News: Dive into MURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
24 days ago
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
GlobeNewswire
a month ago
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
GlobeNewswire
a month ago
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
GlobeNewswire
a month ago
Mural Oncology to Participate in Two Upcoming Investor Conferences
GlobeNewswire
a month ago
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire
3 months ago
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare MURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MURA Mural Oncology plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.